Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Clinical trial NCT06426797 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06426797
- Sponsor
- Peking University People's Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-01
- Primary completion
- 2025-05-01
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.